What is the best anticoagulation regimen for the prevention of cardioembolism from AF in patients with cancer?
Low-molecular-weight heparin agents are commonly used empirically when a hypercoagulable state is suspected in patients with cancer, but the benefit is unclear, particularly in this patient population with a high tendency for hemorrhage.651 A specific situation in these patients that has been more adequately studied is the best anticoagulation regimen for the prevention of cardioembolism from AF,651 which is extrapolated from subgroup analysis of the large ran- domized clinical trials of anticoagulation.